(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist.

Trial Profile

(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Fostamatinib (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms OSKIRA-3
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 04 Jun 2013 Primary endpoint 'Significant difference between fostamatinib (200 then 150 mg/day) + methotrexate and methotrexate in American-College-of-Rheumatology-20%-response-criteria' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top